Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
Transcatheter Technologies GmbH, a emerging medical device company that is developing a next-generation transcatheter aortic heart valve prosthesis, has announced the successful first-in-human implantation of its transapical TRINITY aortic valve designed to be the world's best repositionable heart valve.
"A major limitation of existing transcatheter aortic heart valves is that they cannot be repositioned once implanted. Trinity, however, is designed to solve this difficult problem," said Wolfgang Goetz, MD, PhD, CEO, a cardiac surgeon by training. "With Trinity, once our valve is initially placed, a cardiologist can fully evaluate the valve's function to determine whether it needs to be repositioned, retrieved, or kept in the same position. Equally important, Trinity provides for a controlled positioning by allowing a cardiologist to slowly open the valve stent, thus improving the likelihood of a first-attempt correct placement."
"The TRINITY aortic valve can be positioned precisely. Yet, it also allows for safe repositioning of the valve prosthesis - or even full retrieval - if necessary. Its unique sealing cuff provides excellent results without paravalvular leakage. Moreover, the risk for atrio-ventricular block is dramatically reduced due to the supraannular positioning of TRINITY," added Prof. Christian Hengstenberg, cardiologist at the German Heart Center in Munich.
Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our Heart Disease category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
Technologies, Transcatheter. "Transcatheter Technologies announces successful human implantation of its repositionable TRINITY transapical aortic valve." Medical News Today. MediLexicon, Intl., 30 Oct. 2013. Web.
11 Dec. 2013. <http://www.medicalnewstoday.com/releases/268046>
Technologies, T. (2013, October 30). "Transcatheter Technologies announces successful human implantation of its repositionable TRINITY transapical aortic valve." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact the our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/releases/268046.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2013 All rights reserved. MNT (logo) is the registered trade mark of MediLexicon International Limited.